ORCID "0000-0002-2260-4660" PubMed İndeksli Yayın Koleksiyonu için listeleme
-
Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data
Kimyon, G.; Kalyoncu, U.; Kiraz, S.; Beş, C.; Coşkun, N.; Yağız, B.; Ertenli, I; Mercan, Rıdvan (Clinical & Exper Rheumatology, 2021)Objective To determine the real-life efficacy, safety, and drug-retention rates of leflunomide (LEF) or methotrexate (MTX) as a synthetic DMARD used in combination with biological DMARDs for rheumatoid arthritis (RA). ... -
Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database
Bilgin, E.; Aydın, S. Z.; Tinazzi, Ilaria; Bayındır, Özün; Kimyon, G.; Özişler, Cem; Kalyoncu, Umut; Mercan, Rıdvan (Clinical & Exper Rheumatology, 2021)Objective To explore the impact of early versus late-onset psoriasis (PsO) on the disease characteristics of psoriatic arthritis (PsA) in a large-multicentre cohort. Methods The data from a multicentre psoriatic arthritis ... -
In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?
Yağız, Burcu; Coşkun, Belkıs Nihan; Pehlivan, Yavuz; Dalkılıç, Ediz; Kiraz, Sedat; Yazısız, Veli; Kalyoncu, Umut; Mercan, Rıdvan (Springer Heidelberg, 2021)We wanted to see how close we could get to our goal of treating rheumatoid arthritis (RA) without the use of glucocorticoids (GCs) in the disease-modifying antirheumatic drugs (DMARDs) era using real-life data. Established ...